Addiction Medicine Rounds

*Presented by*

Yale School of Medicine, Department of Internal Medicine

Section of General Medicine

**“Buprenorphine Induction 201: Everything you Need and Want to Know About High and Low Dose Initiation”**

****

**Melissa Weimer, DO, MCR**

Associate Professor of Medicine and Chronic Disease Epidemiology

Director, Yale Addiction Medicine Consult Service

Yale School of Medicine

**Andrew Herring, MD**

Medical Director, CA Bridge

Associate Director of Research,

Highland Hospital,

Alameda Health System

**Kathryn Hawk, MD, MHS**

 **Thursday, January 13th, 2022**

 **2:00pm – 3:00pm**

 **Hosted virtually on Zoom**

[**https://zoom.us/j/98457688379?pwd=WDVCM3lXV1dLNE1OUzhhSDExYSs2Zz09**](https://zoom.us/j/98457688379?pwd=WDVCM3lXV1dLNE1OUzhhSDExYSs2Zz09)

 **Course Directors/Hosts: Jeanette Tetrault & David Fiellin**

 ***There is no corporate or commercial support for this activity***

 This course will fulfill the licensure requirement set forth by the State of Connecticut

**ACCREDITATION**

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**TARGET AUDIENCE**

Faculty, residents, students and staff involved in education of health care professional trainees.

**NEEDS ASSESSMENT**

There is an important need for general internists to understand the value of community level primary care assessment for policy and health planning, and the advantages of community-based participatory research methods for studying health systems.

**LEARNING OBJECTIVES**

1. Describe the unique pharmacology of fentanyl and its analogues.
2. Describe the current evidence regarding buprenorphine induction in people using fentanyl.
3. Discuss the rationale and potential risks and benefits of novel buprenorphine induction strategies.

**DESIGNATION STATEMENT**

The Yale School of Medicine designates this live activity for 1 *AMA PRA Category 1 Credit(s)*™*.* Physicians should only claim the credit commensurate with the extent of their participation in the activity.

**FACULTY DISCLOSURES**

Drs. Weimer and Herring have no conflicts of interest to disclose. Drs. Jeanette Tetrault and David Fiellin: Course Directors, have no conflicts of interest to disclose.

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.